Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,026,833
  • Shares Outstanding, K 109,915
  • Annual Sales, $ 605,220 K
  • Annual Income, $ -168,630 K
  • EBIT $ -170 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.63
  • Price/Sales 3.41
  • Price/Cash Flow N/A
  • Price/Book 5.64

Options Overview Details

View History
  • Implied Volatility 57.24% ( +2.57%)
  • Historical Volatility 57.51%
  • IV Percentile 9%
  • IV Rank 13.61%
  • IV High 116.02% on 10/15/24
  • IV Low 47.98% on 01/27/25
  • Put/Call Vol Ratio 0.80
  • Today's Volume 164
  • Volume Avg (30-Day) 403
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 13,961
  • Open Int (30-Day) 23,010

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.47
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.71
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -30.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.09 +10.97%
on 03/04/25
21.55 -11.97%
on 03/12/25
-0.26 (-1.35%)
since 02/27/25
3-Month
17.09 +10.97%
on 03/04/25
31.17 -39.14%
on 01/02/25
-11.73 (-38.21%)
since 12/27/24
52-Week
11.70 +62.14%
on 04/23/24
34.13 -44.42%
on 12/18/24
+4.33 (+29.58%)
since 03/27/24

Most Recent Stories

More News
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why

Explore the exciting world of NovoCure (NASDAQ: NVCR) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential...

NVCR : 18.97 (+2.87%)
NovoCure (NVCR) Q4 2024 Earnings Call Transcript

NVCR earnings call for the period ending December 31, 2024.

NVCR : 18.97 (+2.87%)
NovoCure Q4 EPS Misses, Revenue Matches

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

NVCR : 18.97 (+2.87%)
MRK : 87.60 (-0.58%)
ZLAB : 36.18 (+6.69%)
RHHBY : 42.3500 (-0.66%)
NovoCure: Q4 Earnings Snapshot

NovoCure: Q4 Earnings Snapshot

NVCR : 18.97 (+2.87%)
Why NovoCure Stock Was Winning Big This Week

Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum...

NVCR : 18.97 (+2.87%)
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances...

NVCR : 18.97 (+2.87%)
ZLAB : 36.18 (+6.69%)
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges

The trial met its primary endpoint, showing a statistically significant improvement in median overall survival.

NVCR : 18.97 (+2.87%)
ZLAB : 36.18 (+6.69%)
NovoCure (NVCR) Q3 2024 Earnings Call Transcript

NVCR earnings call for the period ending September 30, 2024.

NVCR : 18.97 (+2.87%)
NovoCure: Q3 Earnings Snapshot

NovoCure: Q3 Earnings Snapshot

NVCR : 18.97 (+2.87%)
Stocks Mixed on Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.48%. Stocks today are mixed....

UAL : 73.53 (-5.57%)
SYF : 54.16 (-1.88%)
UHS : 186.53 (+1.12%)
IBKR : 169.00 (-2.84%)
ULTA : 370.34 (-0.42%)
CSCO : 61.40 (-0.65%)
CFG : 41.25 (-1.76%)
USB : 43.23 (-1.23%)
$SPX : 5,693.31 (-0.33%)
MS : 119.00 (-2.62%)
JBHT : 150.80 (-0.39%)
EL : 66.95 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 20.00
2nd Resistance Point 19.53
1st Resistance Point 19.25
Last Price 18.97
1st Support Level 18.50
2nd Support Level 18.03
3rd Support Level 17.75

See More

52-Week High 34.13
Fibonacci 61.8% 25.56
Fibonacci 50% 22.92
Fibonacci 38.2% 20.27
Last Price 18.97
52-Week Low 11.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar